Search

PDF - 5142K, CD151 clustering at areas of cell-cell contact in vivo (S1); Cell-cell adhesion in response to CD151 clustering (S2); MAB 1A5 binds to CD151 not engaged with α3 integrin in HEp3 cells (S3); MAb 1A5 recognizes the integrin-binding domain of CD151 (S4); Antibodies that recognize the integrin-binding domain of CD151 mediate clustering at areas of cell-cell contact (S5); CD151 expression in normal and prostate cancer tissue (S6); Expression of integrin α3 is not altered in cancers of the bladder or skin (S7); CD151free detectable in benign and normal prostate tissue does not correspond with patient outcome (S8).

MOV - 8452K, CD151 clustering at areas of cell-cell contact in HEp3 tumor cells.

PDf - 92K, Legends for Supplementary Figures S1-S8 as well as Supplementary Movie S1.

PDF - 67K, Demographic information of patients that underwent RRP at the London Regional Cancer Program between 1994 and 1998 (S1); Pathological and clinical outcomes of patients that underwent RRP at the London Regional Cancer Program between 1994 and 1998 (S2); Demographic information of patients that developed metastasis during follow up at the London Regional Cancer Program between 1994 and 1998 (S3).

Normal physiology relies on the organization of transmembrane proteins by molecular scaffolds, such as tetraspanins. Oncogenesis frequently involves changes in their organization or expression. The tetraspanin CD151 is thought to contribute to cancer progression through direct interaction with the laminin-binding integrins α3β1 and α6β1. However, this interaction cannot explain the ability of CD151 to control migration in the absence of these integrins or on non-laminin substrates. We demonstrate that CD151 can regulate tumor cell migration without direct integrin binding and that integrin-free CD151 (CD151free) correlates clinically with tumor progression and metastasis. Clustering CD151free through its integrin-binding domain promotes accumulation in areas of cell–cell contact, leading to enhanced adhesion and inhibition of tumor cell motility in vitro and in vivo. CD151free clustering is a strong regulator of motility even in the absence of α3 expression but requires PKCα, suggesting that CD151 can control migration independent of its integrin associations. The histologic detection of CD151free in prostate cancer correlates with poor patient outcome. When CD151free is present, patients are more likely to recur after radical prostatectomy and progression to metastatic disease is accelerated. Multivariable analysis identifies CD151free as an independent predictor of survival. Moreover, the detection of CD151free can stratify survival among patients with elevated prostate-specific antigen levels. Cumulatively, these studies demonstrate that a subpopulation of CD151 exists on the surface of tumor cells that can regulate migration independent of its integrin partner. The clinical correlation of CD151free with prostate cancer progression suggests that it may contribute to the disease and predict cancer progression. Cancer Res; 74(1); 173–87. ©2013 AACR.

Primary mucinous cystadenocarcinoma of the retroperitoneum isan extremely rare malignancy with only 2 male patients reportedin the literature. We describe an unusual case presenting as a pelvicmass in a male with previous pan-proctocolectomy and endileostomy for Crohn’s disease and review the available literature.

4633 Background: Renal cell carcinoma (RCC) is the most common neoplasm of the adult kidney. Metastatic RCC is difficult to treat. The five-year survival rate for metastatic RCC is

4613 Background: Xp11.2 translocation renal cell carcinoma (RCC) is a rare tumor with unpredictable clinical course and prognosis in adults. Recognition of these tumors depends on the identification of a RCC with unique histology, particularly clear cell and papillary (CCP) features. Our objectives were to determine the incidence of Xp11.2 translocations in adult RCCs with clear cell and papillary features, and to characterize the clinicopathological features and prognosis of adult Xp11.2 RCCs. Methods: Slides for 1047 RCCs in adults (1999-2009) were retrieved from multiple institutions. Cases were reviewed histologically in order to detect any degree of clear cell and papillary change. Tissue microarrays were constructed from the clear cell and papillary RCCs as well as 40 non-papillary clear cell, 5 papillary, 3 chromophobe and 2 unclassified RCCs. Immunohistochemistry using TFE3, a marker highly sensitive (97.5%) and specific (99.6%) for Xp11.2 translocations was performed. Four pathologists independently reviewed the TFE3 results. Clinical and pathologic data were also retrieved. Results: Out of 1047 RCCs, 140 (13%) exhibited clear cell and papillary features. Four out of these 140 (3%) were positive for TFE3. All of the non-papillary clear cell, papillary, chromophobe and unclassified RCCs were negative for TFE3. Mean follow up for TFE3+ RCCs was 55 months. Conclusions: Xp11.2 translocation RCCs diagnosed by TFE3 immunohistochemistry were identified in 3% of adult RCCs that had clear cell and papillary changes. These tumors appear to present with smaller tumour size, lower stage and better prognosis in comparison to non-Xp11.2 CCPRCC and clear cell RCCs. In addition to Xp11.2 translocation carcinoma, coexistence of clear cell and papillary features may be present in other subsets of tumors that have yet to be characterized. [Table: see text]